Research location
Otwock
Masovian Voivodeship, Poland
Advertisement
Research activity in Otwock
Masovian Voivodeship, PolandCureCurrent currently publishes aggregate city-level research activity for this location: 16 trials and 17 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Otwock
16 linked trials · page 1 of 1A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27 · 1 site observation
RECRUITING
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)NCT07218029 · 2021-05-12 · 1 site observation
RECRUITING
A Study of Mosliciguat in PH-ILDNCT06635850 · 2024-10-29 · 1 site observation
ACTIVE_NOT_RECRUITING
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 · 2023-11-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117 · 2023-06-13 · 1 site observation
TERMINATED
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast CancerNCT05169567 · 2022-03-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)NCT04945460 · 2021-12-29 · 1 site observation
COMPLETED
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)NCT04576988 · 2021-01-25 · 1 site observation
COMPLETED
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117 · 2020-10-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)NCT03924856 · 2019-06-13 · 1 site observation
COMPLETED
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)NCT03898180 · 2019-05-06 · 1 site observation
COMPLETED
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)NCT02134015 · 2014-03-01 · 1 site observation
TERMINATED
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLCNCT01798485 · 2013-04-01 · 1 site observation
TERMINATED
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)NCT01740427 · 2013-02-22 · 1 site observation
COMPLETED
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung CancerNCT01360554 · 2011-06-16 · 2 site observations
COMPLETED
A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung CancerNCT00034268 · 2002-03-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.